Aureus Pharma licenses AurSCOPE Ion Channel Knowledgebase to Xention
Aureus Pharma announces that Xention, a drug discovery and development company focusing on ion channels, has licensed its AurSCOPE Ion Channel Knowledge database.
Ion Channels are an important drug target class as they are involved in many physiological and pathophysiological processes, including cardiac arrhythmias, auto-immune diseases, pain, multiple sclerosis and over active bladder. AurSCOPE Ion Channel is a comprehensive knowledge database containing detailed biological activity that has been described in journals and patents for all known ion channels and their ligands.
"We will use the data contained in the AurSCOPE Ion Channel knowledgebase in combination with our in-house proprietary technology and databases to accelerate the discovery of novel small molecules" said Dr. Dave Madge, Xention´s Vice President of Chemistry. "Access to this knowledge database will help us to use the selectivity profile and ADMET properties of existing drugs to design better molecules for our ion channel targets."
"We are delighted that Xention, an ion channel specialist, has chosen Aureus´ ion channel knowledge database," said Dr. André Michel of Aureus Pharma. "We are confident that the high quality data will complement Xention´s drug discovery platform."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
